Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aridis Pharmaceuticals Inc    ARDS

ARIDIS PHARMACEUTICALS INC

(ARDS)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/10/2019 09/11/2019 09/12/2019 09/13/2019 09/16/2019 Date
10.505(c) 8.33(c) 8.29(c) 8.58(c) 8.04 Last
1 589 69 939 7 353 6 569 5 819 Volume
-3.31% -20.70% -0.48% +3.50% -6.29% Change
More quotes
Financials (USD)
Sales 2019 6,26 M
EBIT 2019 -27,2 M
Net income 2019 -26,0 M
Debt 2019 -
Yield 2019 -
Sales 2020 2,25 M
EBIT 2020 -38,5 M
Net income 2020 -37,6 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -2,91x
P/E ratio 2020 -2,60x
Capi. / Sales2019 12,2x
Capi. / Sales2020 34,0x
Capitalization 76,5 M
More Financials
Company
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs), to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are... 
More about the company
Surperformance© ratings of Aridis Pharmaceuticals Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ARIDIS PHARMACEUTICALS INC
09/09ARIDIS PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (..
AQ
09/08ARIDIS PHARMACEUTICALS : to Present at the H.C. Wainwright 21st Annual Global In..
PR
09/03ARIDIS PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (..
AQ
09/03ARIDIS PHARMACEUTICALS : Reports Phase 2 Clinical Trial Results of AR-105 for th..
PR
08/14ARIDIS PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holde..
AQ
08/12ARIDIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
AQ
08/12ARIDIS PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Fi..
AQ
08/12ARIDIS PHARMACEUTICALS : Entry into a Material Definitive Agreement, Unregistere..
AQ
08/12ARIDIS PHARMACEUTICALS : Announces Second Quarter 2019 Results
PR
07/31ARIDIS PHARMACEUTICALS : Enters Into Equity Purchase and Option Agreements with ..
AQ
More news
Sector news : Bio Therapeutic Drugs
02:48aA Plan to Fight Hep C -- WSJ
DJ
09/03Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
RE
08/29GLOBAL MARKETS LIVE : Dell, United Airlines, UBS, Apple…
08/28U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight
RE
08/28US Judge Mostly Sets Aside Jury Ruling on Repatha Patents -Reuters
DJ
More sector news : Bio Therapeutic Drugs
Chart ARIDIS PHARMACEUTICALS INC
Duration : Period :
Aridis Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 21,75  $
Last Close Price 8,58  $
Spread / Highest target 191%
Spread / Average Target 153%
Spread / Lowest Target 74,8%
EPS Revisions
Managers
NameTitle
Vu L. Truong CEO, Director & Chief Scientific Officer
Eric J. Patzer Chairman
Fred Kurland CFO & Principal Accounting Officer
Wolfgang Dummer Chief Medical Officer
Steven M. Chamow Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ARIDIS PHARMACEUTICALS INC-26.24%76
GILEAD SCIENCES6.35%84 245
VERTEX PHARMACEUTICALS5.57%44 966
REGENERON PHARMACEUTICALS-24.60%30 815
GENMAB27.92%13 161
NEUROCRINE BIOSCIENCES, INC.35.01%8 829